Hexagon Capital Partners’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-5,865
| Closed | -$407K | – | 1171 |
|
|
2025
Q1 | $407K | Sell |
5,865
-729
| -11% | -$50.6K | 0.08% | 122 |
|
|
2024
Q4 | $567K | Buy |
6,594
+704
| +12% | +$60.6K | 0.1% | 95 |
|
|
2024
Q3 | $701K | Sell |
5,890
-55
| -0.9% | -$6.55K | 0.14% | 73 |
|
|
2024
Q2 | $849K | Buy |
5,945
+110
| +2% | +$15.7K | 0.18% | 58 |
|
|
2024
Q1 | $749K | Buy |
5,835
+230
| +4% | +$29.5K | 0.17% | 66 |
|
|
2023
Q4 | $580K | Buy |
5,605
+1,059
| +23% | +$110K | 0.14% | 81 |
|
|
2023
Q3 | $413K | Buy |
4,546
+158
| +4% | +$14.4K | 0.11% | 91 |
|
|
2023
Q2 | $355K | Sell |
4,388
-32
| -0.7% | -$2.59K | 0.09% | 102 |
|
|
2023
Q1 | $352K | Buy |
4,420
+54
| +1% | +$4.3K | 0.1% | 104 |
|
|
2022
Q4 | $295K | Sell |
4,366
-158
| -3% | -$10.7K | 0.09% | 114 |
|
|
2022
Q3 | $225K | Buy |
4,524
+698
| +18% | +$34.7K | 0.07% | 138 |
|
|
2022
Q2 | $213K | Buy |
3,826
+584
| +18% | +$32.5K | 0.06% | 164 |
|
|
2022
Q1 | $180K | Buy |
3,242
+32
| +1% | +$1.78K | 0.05% | 189 |
|
|
2021
Q4 | $180K | Hold |
3,210
| – | – | 0.05% | 189 |
|
|
2021
Q3 | $154K | Buy |
3,210
+58
| +2% | +$2.78K | 0.04% | 186 |
|
|
2021
Q2 | $132K | Hold |
3,152
| – | – | 0.04% | 202 |
|
|
2021
Q1 | $106K | Buy |
3,152
+84
| +3% | +$2.83K | 0.03% | 220 |
|
|
2020
Q4 | $107K | Sell |
3,068
-40
| -1% | -$1.4K | 0.03% | 180 |
|
|
2020
Q3 | $101K | Buy |
+3,108
| New | +$101K | 0.03% | 175 |
|